Naslov
Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis. Data from the STARK project, a prospective international, multicenter, cohort study

Autori
Kardenas Jaen, Karina ; Archibugi, Livia ; Poropat, Goran ; Korpela, Taija ; Capurso, Gabriele ; Maissoneuve, Patrick ; Aparicio, JR ; Cassellas, JA ; Arcidiacono, Paolo Giorgio ; Mariani, A ; Štimac, Davor ; Hauser, Goran ; Udd, A ; Kylanpaa L, Rainio, M ; Di Giulio, E ; Vanella, G ; Lohr, Matthias ; Valente, Roberto ; Arnelo, U ; De Pretis, Nicolo ; de-Madaria, Enrique

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Pancreatology / - , 2019, S189-S190

Skup
XVI Pancreatology Spanish Association Meeting 2019

Mjesto i datum
Bilbao, Španjolska, 19.09.2019. - 21.09.2019

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Statins ; post-ERCP pancreatitis ; prevention

Sažetak
Introduction: Acute Pancreatitis (AP) is the most frequent complication after Endoscopic Retrograde Cholangiopancreatography (ERCP). Some prophylactic strategies are the use of pancreatic stents or peri-procedural nonsteroidal anti-inflammatory drugs (NSAIDs). Statins are widely used lipid-lowering drugs. Recent studies suggest that chronic statin intake may be associated to a lower incidence of AP. Methods: Our aim is to investigate whether chronic statin and/or acetylsalicylic acid (ASA) intake is associated to a lower incidence of PEP. Stark project is an international, multicenter, prospective, cohort study, developed under the auspices of “Pancreas 2000”. Consecutive patients undergoing ERCP in seven european centers, older than 18, were included prospectively. Demographic and medical data were retrieved by anamnesis. Patients were followed-up to detect those with PEP. The sample size was estimated to be 1, 016 participants. A univariate analysis and multivariate analysis (binary logistic regression) were performed. Results: 1150 patients were included. Mean age was 68.4 years (SD 14.5). 561 (48.8%) patients were female. 70 patients developed post-ERCP-AP (PEP) (6.1%) ; 25 patients (8.1%) under chronic statin treatment versus 45 patients (5.4%) who do not (p= 0.086). Multivariate analysis showed an aOR of 1.679 (0.941-2.994), p 0.079 for PEP incidence in statin users. Regarding ASA consumption, 11 patients (6.6%) under ASA treatment versus 59 patients (6%) who were not consuming ASA, developed PEP (p= 0.753). Multivariate analysis showed an aOR of 1.017 (0.487-2.127), p=0.963 for PEP incidence among ASA users. Conclusion: Our data suggest that chronic statin and/or ASA intake isnt statistically associated to an increase incidence of PEP.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA